On Tuesday, February 19th, FDA published a draft guidance for medical device makers which identifies a process for companies to request nonbinding feedback on certain FDA Form 483 deficiencies noted during pre or postmarket inspections.
In its draft guidance, FDA states that the intention of nonbinding feedback is to inform a Sponsor’s implementation of actions in response to inspectional observations. Nonbinding feedback can help medical device companies determine if certain proposed actions would be adequate, therefore avoiding unnecessary investment in solutions which would not satisfactorily address the inspectional observations. In 2017, section 704(h)(2) was added to the Federal Food, Drug, & Cosmetic (FD&C) Act, requiring FDA to provide nonbinding feedback within 45 days of receiving a Sponsor’s request.
A request for nonbinding feedback “should come from the person to whom FDA issues the Form FDA 483 or from someone who can otherwise demonstrate to the Agency that they are the owner, operator, or agent in charge of the establishment or a designated representative of such person(s).” The request should be sent to the FDA contact identified to receive the response to the Form FDA and must be made in a ‘timely manner,’ which is defined to be no more than 15 business days after the 483 is issued.
Requests for nonbinding feedback should be submitted with the response to the 483. FDA notes that, although it is being submitted with the response, requests should be a distinctly separate document and should include a cover letter that includes:
Under Section 704(h)(2), “a request for nonbinding feedback must describe how one or more observations ‘involve a public health priority,’ ‘implicate systemic or major actions,’ or ‘relate to emerging safety issues (as determined by [FDA]).’” In the draft guidance, FDA provides three situations where the request for nonbinding feedback will meet these criteria:
Requests for nonbinding feedback should contain justification explaining in detail why the requestor believes that one or more of the eligibility criteria are met. If one or more have been met, the FDA is required to provide nonbinding feedback; if none of the criteria have been met, providing nonbinding feedback is not required.
In addition to the eligibility criteria justifications, the request for nonbinding feedback should state the proposed actions in response to the observation(s). These actions should include a detailed description and timeline of the activities the firm plans to take to correct the conditions described in the observations, and how to prevent future recurrence. Submissions should include any supporting documentation for the FDA to adequately evaluate the proposed actions.
If one or more of the eligibility criteria have been met, FDA is required to provide nonbinding feedback within 45 calendar days of receiving the request. The Agency’s feedback should identify whether the proposed actions appear adequate, partially adequate, or inadequate to address inspectional observations. If the proposed actions are determined to be “partially adequate or inadequate, FDA intends to:
Nonbinding feedback is the Agency’s best recommendation for the establishment’s specific factual circumstances based on the information provided in the request. This feedback is intended to be used to inform the firm’s implementation of actions in response to inspectional observations and is not required to be implemented by the medical device company. If implemented, nonbinding feedback does not exempt the company from receiving FDA cited inspectional observations or other regulatory action. It is the responsibility of the owners, operators, and agents to ensure compliance with all FDA rules, regulations, and requirements.
FDA issued this draft guidance for comment purposes only and is asking interested individuals to provide written or electronic feedback by April 22, 2019.
Are you in the process of developing an FDA-regulated medical device? We can help with all facets of the device approval process, working with you along the way to achieve successful interactions with the FDA. To learn more about our 35-year track record of helping our clients obtain favorable results with the Agency and to find out how we can help you do the same thing, contact us today.
February 11, 2016
On February 9, 2016, the FDA published a draft guidance entitled “Display Devices for Diagnostic Radiology.” The document, which will replace a 2008 guidance (“Display Accessories for Full-Field...
August 20, 2018
On Thursday, August 16th, the FDA released a list of medical device accessories that have the potential to be reclassified as class I devices. Background According to section 513 of the Food, Drug, &...
August 31, 2015
Earlier this year, FDA published a report announcing that the Agency’s device program has shown “a pattern of markedly improved performance.” Over the past five years, FDA has been working to improve...